In this Fierce Pharma article, our CEO Richard Pops discusses how our deep expertise in #neuroscience and advanced molecular design capabilities are fueling our path forward. Read the full article to learn more about the evolution of our company’s focus and how we are working to make a lasting difference for patients: https://lnkd.in/gtRkbcvm
Alkermes
Biotechnology Research
Alkermes is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience.
About us
At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized. Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions. Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers and broader impacted communities. We remain committed to patient engagement, responsible and sustainable operations, and equitable access to quality treatment. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. See our Community Guidelines: https://www.alkermes.com/social-community-guidelines
- Website
-
https://www.alkermes.com/
External link for Alkermes
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Dublin
- Type
- Public Company
- Founded
- 1987
- Specialties
- Pharma, Pharmaceutical, Sales, Marketing, IT, CNS, Addiction, Information technology, Human Resources, Sales, District Sales, Regional Sales, Research & Development, R&D, Manufacturing, Medical Affairs, serious mental illness, biotech, addiction, narcolepsy, neuroscience, sleep disorders, and biotech
Locations
-
Primary
Connaught House
1 Burlington Road
Dublin, IE
-
900 Winter St
Waltham, Massachusetts 02451, US
-
265 Olinger Circle
Wilmington, OH 45177, US
Employees at Alkermes
Updates
-
Summer road trips await, but for those in the #narcolepsy community, traveling can bring unique challenges. When driving far distances, it's essential to prioritize safety and well-being with considerations for symptoms associated with the sleep disorder. Check out these tips for managing narcolepsy while on the road.
-
If you or someone you love is living with #opoidusedisorder or #alcoholusedisorder, this resource from Shatterproof may help raise awareness of the support systems, treatment options and other resources that exist. https://bit.ly/3xQfHDQ https://bit.ly/3xQfHDQ
-
Did you know that there are multiple types of stigma? For people living with serious #mentalillness, stigma may affect their decision to seek treatment. Whether subtle or obvious, stigma surrounding #mentalillness can be harmful. This American Psychiatric Association resource provides education on the different types of stigma, its harmful effects, and how we can collectively work to reduce stigma: https://bit.ly/3xQVFJr
-
Happy #4thofJuly! #TeamAlkermes wishes all of our U.S. colleagues a happy, healthy and enjoyable celebration.
-
Marisa Borgasano, #TeamAlkermes' Sr Dir, SMI and Addiction Communications and Advocacy is speaking next week at Fierce Pharma's annual PR & Communications Summit. Learn more: https://bit.ly/3VPV9Ub
-
Formally recognized since 2008, #BIPOCMentalHealthMonth results from Bebe Moore Campbell’s work to raise awareness for the #mentalhealth needs of the Black community and other underrepresented communities. Sixteen years later, we celebrate the progress that’s been made, and recognize there is still work to be done. As #TeamAlkermes marks this month, we’re committed to taking action to promote mental health equity. The Centers for Disease Control and Prevention outlines actions we can all take in service of building a more equitable future in mental health: https://bit.ly/3L8epaw
-
July is #DisabilityPrideMonth! #TeamAlkermes honors the unique and varied contributions that members of the disability community have made to our company and our world at large. To learn more about this important observance, visit this page from The Arc of the United States: https://bit.ly/3XGPRwJ
-
Independence Day is quickly approaching, and so are the celebrations! As we gear up for holiday gatherings, you may be reconsidering the choice to consume alcohol. If that rings true, this resource from MedlinePlus provides tips and considerations to help reduce or quit drinking altogether: https://lnkd.in/gvvKYUw4
-
The final days of #MensHealthMonth are here! While both men and women can be diagnosed with #bipiolardisorder, there are specific gender differences in how the condition presents. This resource from the International Bipolar Foundation breaks down symptoms of bipolar disorder in men to be aware of: https://lnkd.in/gEKRutaR